Navigation Links
Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
Date:7/14/2008

t program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborator, in connection with the development and commercialization of Genaera's IL-9 antibody program; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.

Contact:

Genaera Corporation Shirley Chow - Porter Novelli Life Sciences

Investor Relations Media

(610) 941-5675 (212) 601-8308

http://www.genaera.com schow@pnlifesciences.com


'/>"/>
SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
2. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
3. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
4. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
5. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
8. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
9. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... issued the following open letter to shareholders from ... Med. Sc. Dear RXi Shareholders, ... of inaccurate statements posted on certain social media ...
(Date:12/22/2014)... Dec. 22, 2014  Pfenex Inc. (NYSE MKT: PFNX) ... vaccine, has been filed and is now open and ... the Department of Health and Human Services (HHS), through ... "We are extremely pleased to have the IND ... represents a significant milestone in our company,s partnership with ...
(Date:12/19/2014)... -- In the Friday, December 19 edition of USA ... Technology (HIT) features Konica Minolta, the company announced today. The supplement ... leading healthcare organizations. In addition to the print ... as New York , Chicago ... Minneapolis and San Francisco ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2
... Ambrx Inc. today announced that Ho Cho, Ph.D., ... from the company,s antibody drug conjugate (ADC) programs at ... obtained from recent xenograft studies comparing Ambrx ADCs with ... technology has been clinically validated as safe and efficacious ...
... 22, 2011 Naurex Inc., a clinical-stage ... psychiatry and neurology, today announced that it has initiated ... GLYX-13.  GLYX-13, a Glycine-site Functional Partial Agonist (GFPA) selective ... developed as a therapy for patients who are not ...
Cached Medicine Technology:Ambrx to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences 2Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 2Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 3
(Date:12/22/2014)... December 22, 2014 The Bob ... ever, having invested more than $5 million in ... veterans and their families. , This includes $1.3 ... dozen nonprofits, helping with: veteran entrepreneurship; community impact; ... life-coaches for severely injured veterans. , “The needs ...
(Date:12/22/2014)... 2014 Give a loved one the ... of health and vitality. , For a limited time, ... anti-aging formulas in special Holiday Wellness gift packages at ... , Each bottle contains cutting-edge, proven nutritional support for ... as well as we age. , Joint ...
(Date:12/22/2014)... 22, 2014 Xarelto Lawsuit News ... of judges has granted a request to centralize pending ... District Court, Eastern District of Louisiana. The U.S. Judicial ... December 12 to transfer over 50 Xarelto cases–21 lawsuits ... the Louisiana court for consolidation under U.S. District Judge ...
(Date:12/22/2014)... St. Petersburg, FL (PRWEB) December 22, 2014 ... needed. Sublime Beauty® has a fast and easy solution that ... online gift cards can be purchased from from $25 up ... ®. "We offer 100% customer satisfaction and a wide array ... cards have no fees and no expiration dates. , ...
(Date:12/22/2014)... December 22, 2014 The ... professional development programs this month. Faculty have been ... on nurse educators fast-tracked for administrative leadership roles ... Development Program for Simulation Educators, featuring a curriculum ... of nursing education. , Twenty nurse educators ...
Breaking Medicine News(10 mins):Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3
... is marking its first National Women and Girls HIV/AIDS ... Fauci, MD, director of the National Institute of Allergy ... Health (NIH) // said in a press release, “This ... increasing impact of HIV/AIDS on women and girls in ...
... a zone in Torun, in northern Poland on the bank of ... Polish vets confirmed the presence of the H5N1 bird flu virus ... the German border but the vets did not confirm whether the ... put by Tadeusz Wijaszka, director of the national laboratory in Pulawy, ...
... passage, which results due to smoking is said to ... ,Called Chronic Obstructive Pulmonary Disease (COPD), ... and emphysema of the lungs. ,Unlike simple ... the mucous membrane and emphysema decomposes lung tissue. People ...
... breast cancer victims is denied by the NHS to victims ... private medical insurers have saved their day by pitching in. ... available this drug to almost 100 women, who have been ... the drug available in 30 such cases. ,It ...
... favor of the rise in Medicare bulk billing, which is ... Health Minister Tony Abbott released some alarming statistics that show ... ,According to Dr Kim Bulwinkel, from AMA Queensland, ... more patients, in order to make it a feasible option. ...
... that the risk of the H5N1 strain reaching Australia was ... the French parliamentary commission on the disease and put the ... ,It said that the avian flu was likely to ... chief vet Gardner Murray has rejected the world animal health ...
Cached Medicine News:
...
Lacrimal Cannula, Straight, Stepped DownSize: 19g x 1-1/2"....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: